FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132274865> ?p ?o ?g. }

• W3132274865 endingPage "e330" @default.
• W3132274865 startingPage "e320" @default.
• W3132274865 abstract "BackgroundThe rate of diagnostic testing for malaria is still very low in Nigeria despite the scale-up of malaria rapid diagnostic test (MRDT) availability, following WHO's recommendation of universal diagnostic testing in 2010. We investigated whether a social group sensitisation and education intervention (social group intervention) and a social group intervention plus health-care provider training intervention would increase the demand (use or request, or both) for MRDTs among community members in Ebonyi state, Nigeria.MethodsWe did a three-arm, parallel, open-label, stratified cluster-randomised controlled trial in Ebonyi state, Nigeria, to evaluate the effects of two interventions compared with a control. We randomly assigned geographical clusters that were accessible (close to a road that was drivable even during the rainy seasons) and had at least one eligible public primary health facility and patent medicine vendor (those that offered MRDT services) in a 1:1:1 allocation to the control arm (receiving no intervention), social group arm (receiving sensitisation and education about MRDT), or social group plus provider arm (receiving the social group intervention plus provider training in health communication about MRDT). Investigators, participants (social groups, providers, respondents), and interviewers could not be masked to group assignments. The primary outcome was the proportion of children younger than 5 years with fever or malaria-like illness, in the 2 weeks preceding a household survey, who received an MRDT, and the coprimary outcome was the same outcome but among children aged 5 years and older (ie, up to and including 17 years) and adults (excluding pregnant women). The outcomes were measured at an individual level via household surveys before the interventions and 3 months after the end of the interventions. All analyses were done using a cluster-level method on an intention-to-treat basis. This trial is registered with ISRCTN, number ISRCTN14046444.FindingsWe carried out eligibility screening and recruitment of participants (clusters, social groups, and providers) between July 2 and Sept 27, 2018. 34 clusters met the eligibility criteria and 18 were randomly selected to participate and randomly assigned to arms (six clusters per arm). A mean proportion of 40·6% (SD 14·5) of eligible children younger than 5 years in the control arm received an MRDT, versus 66·7% (11·7) in the social group arm (adjusted risk difference [aRD] 28·8%, 95% CI 21·9–35·7, p<0·0001) and 71·7% (19·8) in the social group plus provider arm (aRD 32·7%, 24·9–40·5, p<0·0001), with no significant difference between the social group arm and the social group plus provider arm. A mean proportion of 36·3% (18·5) of eligible children aged 5 years and older in the control arm received an MRDT, versus 60·7% (14·0) in the social group arm (aRD 25·6%, 16·8–34·4, p=0·0004), and 59·5% (18·3) in the social group plus provider arm (aRD 28·0%, 19·5–36·5, p=0·0002), with no significant difference between the social group arm and the social group plus provider arm.InterpretationThe sensitisation and education of social groups about MRDTs can significantly increase the demand for MRDTs. This intervention is pragmatic and could be applied within malaria control or elimination programmes, in Nigeria and in other high-burden countries, to enhance diagnostic testing for patients suspected of having malaria.FundingThere was no funding source for this study. The rate of diagnostic testing for malaria is still very low in Nigeria despite the scale-up of malaria rapid diagnostic test (MRDT) availability, following WHO's recommendation of universal diagnostic testing in 2010. We investigated whether a social group sensitisation and education intervention (social group intervention) and a social group intervention plus health-care provider training intervention would increase the demand (use or request, or both) for MRDTs among community members in Ebonyi state, Nigeria. We did a three-arm, parallel, open-label, stratified cluster-randomised controlled trial in Ebonyi state, Nigeria, to evaluate the effects of two interventions compared with a control. We randomly assigned geographical clusters that were accessible (close to a road that was drivable even during the rainy seasons) and had at least one eligible public primary health facility and patent medicine vendor (those that offered MRDT services) in a 1:1:1 allocation to the control arm (receiving no intervention), social group arm (receiving sensitisation and education about MRDT), or social group plus provider arm (receiving the social group intervention plus provider training in health communication about MRDT). Investigators, participants (social groups, providers, respondents), and interviewers could not be masked to group assignments. The primary outcome was the proportion of children younger than 5 years with fever or malaria-like illness, in the 2 weeks preceding a household survey, who received an MRDT, and the coprimary outcome was the same outcome but among children aged 5 years and older (ie, up to and including 17 years) and adults (excluding pregnant women). The outcomes were measured at an individual level via household surveys before the interventions and 3 months after the end of the interventions. All analyses were done using a cluster-level method on an intention-to-treat basis. This trial is registered with ISRCTN, number ISRCTN14046444. We carried out eligibility screening and recruitment of participants (clusters, social groups, and providers) between July 2 and Sept 27, 2018. 34 clusters met the eligibility criteria and 18 were randomly selected to participate and randomly assigned to arms (six clusters per arm). A mean proportion of 40·6% (SD 14·5) of eligible children younger than 5 years in the control arm received an MRDT, versus 66·7% (11·7) in the social group arm (adjusted risk difference [aRD] 28·8%, 95% CI 21·9–35·7, p<0·0001) and 71·7% (19·8) in the social group plus provider arm (aRD 32·7%, 24·9–40·5, p<0·0001), with no significant difference between the social group arm and the social group plus provider arm. A mean proportion of 36·3% (18·5) of eligible children aged 5 years and older in the control arm received an MRDT, versus 60·7% (14·0) in the social group arm (aRD 25·6%, 16·8–34·4, p=0·0004), and 59·5% (18·3) in the social group plus provider arm (aRD 28·0%, 19·5–36·5, p=0·0002), with no significant difference between the social group arm and the social group plus provider arm. The sensitisation and education of social groups about MRDTs can significantly increase the demand for MRDTs. This intervention is pragmatic and could be applied within malaria control or elimination programmes, in Nigeria and in other high-burden countries, to enhance diagnostic testing for patients suspected of having malaria." @default.
• W3132274865 created "2021-03-01" @default.
• W3132274865 creator A5008096837 @default.
• W3132274865 creator A5011083484 @default.
• W3132274865 creator A5013109121 @default.
• W3132274865 creator A5024299177 @default.
• W3132274865 creator A5024470866 @default.
• W3132274865 creator A5027106974 @default.
• W3132274865 creator A5030565523 @default.
• W3132274865 creator A5044560644 @default.
• W3132274865 creator A5057381969 @default.
• W3132274865 creator A5062131244 @default.
• W3132274865 creator A5068197718 @default.
• W3132274865 creator A5070227285 @default.
• W3132274865 creator A5086376289 @default.
• W3132274865 creator A5086383957 @default.
• W3132274865 creator A5091767044 @default.
• W3132274865 date "2021-03-01" @default.
• W3132274865 modified "2023-09-27" @default.
• W3132274865 title "Social group and health-care provider interventions to increase the demand for malaria rapid diagnostic tests among community members in Ebonyi state, Nigeria: a cluster-randomised controlled trial" @default.
• W3132274865 cites W1531989075 @default.
• W3132274865 cites W1648137791 @default.
• W3132274865 cites W1983409249 @default.
• W3132274865 cites W2026723594 @default.
• W3132274865 cites W2085503847 @default.
• W3132274865 cites W2105842235 @default.
• W3132274865 cites W2118262785 @default.
• W3132274865 cites W2138751974 @default.
• W3132274865 cites W2236020037 @default.
• W3132274865 cites W2252078284 @default.
• W3132274865 cites W2275380692 @default.
• W3132274865 cites W2511176882 @default.
• W3132274865 cites W2613150879 @default.
• W3132274865 cites W2883527120 @default.
• W3132274865 cites W2894656887 @default.
• W3132274865 cites W2920032315 @default.
• W3132274865 cites W2951478348 @default.
• W3132274865 cites W2979649827 @default.
• W3132274865 doi "https://doi.org/10.1016/s2214-109x(20)30508-8" @default.
• W3132274865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33607030" @default.
• W3132274865 hasPublicationYear "2021" @default.
• W3132274865 type Work @default.
• W3132274865 sameAs 3132274865 @default.
• W3132274865 citedByCount "3" @default.
• W3132274865 countsByYear W31322748652021 @default.
• W3132274865 countsByYear W31322748652023 @default.
• W3132274865 crossrefType "journal-article" @default.
• W3132274865 hasAuthorship W3132274865A5008096837 @default.
• W3132274865 hasAuthorship W3132274865A5011083484 @default.
• W3132274865 hasAuthorship W3132274865A5013109121 @default.
• W3132274865 hasAuthorship W3132274865A5024299177 @default.
• W3132274865 hasAuthorship W3132274865A5024470866 @default.
• W3132274865 hasAuthorship W3132274865A5027106974 @default.
• W3132274865 hasAuthorship W3132274865A5030565523 @default.
• W3132274865 hasAuthorship W3132274865A5044560644 @default.
• W3132274865 hasAuthorship W3132274865A5057381969 @default.
• W3132274865 hasAuthorship W3132274865A5062131244 @default.
• W3132274865 hasAuthorship W3132274865A5068197718 @default.
• W3132274865 hasAuthorship W3132274865A5070227285 @default.
• W3132274865 hasAuthorship W3132274865A5086376289 @default.
• W3132274865 hasAuthorship W3132274865A5086383957 @default.
• W3132274865 hasAuthorship W3132274865A5091767044 @default.
• W3132274865 hasBestOaLocation W31322748651 @default.
• W3132274865 hasConcept C126322002 @default.
• W3132274865 hasConcept C159110408 @default.
• W3132274865 hasConcept C160735492 @default.
• W3132274865 hasConcept C162324750 @default.
• W3132274865 hasConcept C164866538 @default.
• W3132274865 hasConcept C168563851 @default.
• W3132274865 hasConcept C176400912 @default.
• W3132274865 hasConcept C199360897 @default.
• W3132274865 hasConcept C203014093 @default.
• W3132274865 hasConcept C27415008 @default.
• W3132274865 hasConcept C2778048844 @default.
• W3132274865 hasConcept C41008148 @default.
• W3132274865 hasConcept C50522688 @default.
• W3132274865 hasConcept C512399662 @default.
• W3132274865 hasConcept C71924100 @default.
• W3132274865 hasConcept C99454951 @default.
• W3132274865 hasConceptScore W3132274865C126322002 @default.
• W3132274865 hasConceptScore W3132274865C159110408 @default.
• W3132274865 hasConceptScore W3132274865C160735492 @default.
• W3132274865 hasConceptScore W3132274865C162324750 @default.
• W3132274865 hasConceptScore W3132274865C164866538 @default.
• W3132274865 hasConceptScore W3132274865C168563851 @default.
• W3132274865 hasConceptScore W3132274865C176400912 @default.
• W3132274865 hasConceptScore W3132274865C199360897 @default.
• W3132274865 hasConceptScore W3132274865C203014093 @default.
• W3132274865 hasConceptScore W3132274865C27415008 @default.
• W3132274865 hasConceptScore W3132274865C2778048844 @default.
• W3132274865 hasConceptScore W3132274865C41008148 @default.
• W3132274865 hasConceptScore W3132274865C50522688 @default.
• W3132274865 hasConceptScore W3132274865C512399662 @default.
• W3132274865 hasConceptScore W3132274865C71924100 @default.
• W3132274865 hasConceptScore W3132274865C99454951 @default.
• W3132274865 hasIssue "3" @default.
• W3132274865 hasLocation W31322748651 @default.
• W3132274865 hasOpenAccess W3132274865 @default.

• next